Coherus Oncology, Inc. Common Stock (CHRS) — Analysis Summary
Coherus Oncology, Inc. Common Stock (CHRS) has a market cap of $223.66M with year-over-year revenue growth of -84.2%. Net margin stands at 398.4%. The stock trades at a P/E ratio of 1.2.
Key Takeaways
- Revenue changed -84.2% year-over-year
- Net margin of 398.4%
- P/E ratio of 1.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, CHRS posted revenue growth of -84.2% and trades at a P/E of 1.2.
Coherus Oncology, Inc. Common Stock (CHRS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -19.0x — earnings do not cover interest payments
Operating margin at -366.6% — severe operating losses
Operating cash flow is negative while net income remains positive.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
145
Headquarters
REDWOOD CITY, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.